BASEL, Switzerland,
Feb. 9 /PRNewswire/ - Neuro-Biotech
Corporation (PINKSHEET: MRES) (OTCQB: MRES), having recently signed
a Business Development Agreement with Russian based Credo-TM, who
in turn had just finished negotiations for 1,000,000 Post Traumatic
Stress Disorder (PTSD) test with their nation's military forces to
help with early detection of PTSD which is an ongoing concern for
worldwide military forces.
Stress, as defined by Hans Selye in 1945, could be expressed in
regards to active military people first as a physical stress - we
know that active military people are trained to be able to
physically react to specific situations. It could also be expressed
as a mental stress - active military people are also well trained
in regards to alertness, vigilance, attention or automatisms
related to their equipments. Finally, it can be expressed too in
the form of emotional stress - it is the link to work with
PTSD.
The human emotional memory is the basis of PTSD. In fact, the
brain is used to receive all kind of information through our five
senses, to retain and integrate it, to remember and initiate the
emotions through "FLASHBACKS". In PTSD, such emotional
information is so strong that it is impossible to forget it.
However, it is possible to manage with it through recognition and
acceptation process.
Some statistical data have clearly demonstrated that PTSD is
present in the population. Thus, in USA, 5,600,000 people are
affected, 1,600,000 in Germany,
1,200,000 in France, 1,600,000 in
Egypt while in Switzerland, less than 200,000 people are
affected by PTSD. These data are in good correlation with the WHO
saying in its 2000's Report "Stress - a century's disease".
For more information on Neuro-Biotech Corp or to contact a
company representative, please visit: www.neuro-biotechcorp.com
CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions,
and that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or
obligation to update or revise forward-looking information, whether
as a result of new information, future events, or otherwise, could
cause the company's actual results to differ materially from those
indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright b. 9 PR Newswire